Severe hepatocellular injury after hematopoietic cell transplant: incidence, etiology and outcome
- PMID: 19308033
- PMCID: PMC2762005
- DOI: 10.1038/bmt.2009.56
Severe hepatocellular injury after hematopoietic cell transplant: incidence, etiology and outcome
Abstract
Hepatic complications of transplant are a common cause of mortality. Although mild elevations of serum aminotransferase enzymes (aspartate and alanine (AST, ALT)) do not carry an adverse prognosis, this is not the case with severe hepatocellular injury. We reviewed 6225 consecutive recipients to determine the incidence and outcomes of severe hepatocellular injury (AST >1500 U/l) before day 100, which occurred in 88 patients. Causes were sinusoidal obstruction syndrome (SOS) (n = 46), hypoxic hepatitis (n = 33), varicella zoster virus (VZV) hepatitis (n = 4), drug-liver injury (n = 2) and unknown (n = 3). The incidence declined from 1.9% in the 1990s to 1.1% recently (owing to a fivefold decline in SOS and disappearance of VZV hepatitis). In hypoxic hepatitis, peak serum AST was 3545 U/l (range, 1380-25 246) within days of shock or prolonged hypoxemia; case fatality rate was 88%. In SOS, AST increases occurred 2-6 weeks after diagnosis; peak AST was 2252 U/l (range, 1437-8281); case fatality rate was 76%, with only serum bilirubin able to distinguish survivors (2.7 vs 11.3 mg/100 ml, P=0.0009). We conclude that circulatory insults (sinusoidal injury, hypotension and hypoxemia), and not infection, are the most common cause of severe hepatocellular injury, the frequency of which has declined because of a falling incidence of SOS and VZV hepatitis.
Figures

Similar articles
-
Defibrotide for Patients with Hepatic Veno-Occlusive Disease/Sinusoidal Obstruction Syndrome: Interim Results from a Treatment IND Study.Biol Blood Marrow Transplant. 2017 Jun;23(6):997-1004. doi: 10.1016/j.bbmt.2017.03.008. Epub 2017 Mar 8. Biol Blood Marrow Transplant. 2017. PMID: 28285079
-
Burden of illness associated with sinusoidal obstruction syndrome/veno-occlusive disease in patients with hematopoietic stem cell transplantation.J Med Econ. 2017 Aug;20(8):871-883. doi: 10.1080/13696998.2017.1336623. Epub 2017 Jun 14. J Med Econ. 2017. PMID: 28562132
-
Sinusoidal Obstruction Syndrome/Veno-Occlusive Disease after Unmanipulated Haploidentical Hematopoietic Stem Cell Transplantation with Post-Transplantation Cyclophosphamide: A Study on Behalf of the Spanish Hematopoietic Stem Cell Transplantation and Cellular Therapy Group (GETH).Transplant Cell Ther. 2024 Sep;30(9):914.e1-914.e8. doi: 10.1016/j.jtct.2024.06.003. Epub 2024 Jun 7. Transplant Cell Ther. 2024. PMID: 38851323
-
Hepatic sinusoidal obstruction syndrome/veno-occlusive disease after hematopoietic cell transplantation: historical and current considerations in Korea.Korean J Intern Med. 2021 Nov;36(6):1261-1280. doi: 10.3904/kjim.2021.082. Epub 2021 Sep 24. Korean J Intern Med. 2021. PMID: 34555279 Free PMC article. Review.
-
Sinusoidal obstruction syndrome (hepatic veno-occlusive disease).J Clin Exp Hepatol. 2014 Dec;4(4):332-46. doi: 10.1016/j.jceh.2014.10.002. Epub 2014 Oct 30. J Clin Exp Hepatol. 2014. PMID: 25755580 Free PMC article. Review.
Cited by
-
In vivo adenine base editing rescues adrenoleukodystrophy in a humanized mouse model.Mol Ther. 2024 Jul 3;32(7):2190-2206. doi: 10.1016/j.ymthe.2024.05.027. Epub 2024 May 24. Mol Ther. 2024. PMID: 38796705 Free PMC article.
-
Early Endothelial Activation in a Mouse Model of Graft vs Host Disease Following Chemotherapy.Front Immunol. 2021 Aug 5;12:708554. doi: 10.3389/fimmu.2021.708554. eCollection 2021. Front Immunol. 2021. PMID: 34421913 Free PMC article.
-
Veno occlusive disease: update on clinical management.World J Gastroenterol. 2007 Aug 7;13(29):3918-24. doi: 10.3748/wjg.v13.i29.3918. World J Gastroenterol. 2007. PMID: 17663504 Free PMC article.
-
Hepatobiliary complications of hematopoietic cell transplantation, 40 years on.Hepatology. 2010 Apr;51(4):1450-60. doi: 10.1002/hep.23533. Hepatology. 2010. PMID: 20373370 Free PMC article. Review.
-
Endothelial Dysfunction Syndromes after Allogeneic Stem Cell Transplantation.Cancers (Basel). 2023 Jan 22;15(3):680. doi: 10.3390/cancers15030680. Cancers (Basel). 2023. PMID: 36765638 Free PMC article. Review.
References
-
- Strasser SI, McDonald GB. Gastrointestinal and hepatic complications. In: Appelbaum FR, Forman SJ, Negrin RS, Blume KG, editors. Thomas' Hematopoietic Cell Transplantation. Fourth. Oxford, UK: Wiley-Blackwell Publishing; 2009. pp. 1434–1455.
-
- Gooley TA, Rajvanshi P, Schoch HG, McDonald GB. Serum bilirubin levels and mortality after myeloablative allogeneic hematopoietic cell transplantation. Hepatology. 2005;41:345–52. - PubMed
-
- El-Sayed MH, El-Haddad A, Fahmy OA, Salama II, Mahmoud HK. Liver disease is a major cause of mortality following allogeneic bone-marrow transplantation. European Journal of Gastroenterology & Hepatology. 2004;16:1347–54. - PubMed
-
- Kim B, Chung K, Sun H, Suh J, Min W, Kang C, et al. Liver disease during the first posttransplant year in bone marrow transplantation recipients: retrospective study. Bone Marrow Transplantation. 2000;26:193–7. - PubMed
-
- McDonald GB. Management of hepatic disease following hematopoietic cell tranplant. Alimentary Pharmacology & Therapeutics. 2006;24:441–52. - PubMed
Publication types
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources